REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugsREGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugs

For research purposes only. Full disclaimer →

Stack Library

Immune Fortifier

Immune Supportbeginner
30
Share
Peptides

2

Avg Daily mcg

479

Level

beginner

Added

May 16, 2026

Overview

The Immune Fortifier is a beginner-friendly peptide stack designed to strengthen and modulate the immune system through two complementary pathways: thymic restoration and antimicrobial defense. This protocol pairs Thymosin Alpha-1, a naturally occurring thymic peptide responsible for immune cell maturation, with LL-37, a human cathelicidin antimicrobial peptide that serves as a first-line innate defense molecule. Thymosin Alpha-1 at 1500mcg twice per week enhances T-cell differentiation, promotes dendritic cell maturation, and modulates cytokine balance between Th1 and Th2 responses. Originally isolated from thymic tissue, this peptide has been extensively studied for its ability to restore immune competence in immunocompromised individuals and has regulatory approval in over 35 countries for hepatitis and as an immune adjuvant. LL-37 at 100mcg every other day provides broad-spectrum antimicrobial activity against bacteria, viruses, and fungi while also modulating inflammatory signaling to prevent excessive immune activation. The synergy between these peptides lies in their complementary mechanisms: Thymosin Alpha-1 strengthens adaptive immune surveillance and long-term immune memory, while LL-37 bolsters innate frontline defenses and barrier integrity. Together, they create a more robust and balanced immune response without overstimulation. Administer Thymosin Alpha-1 subcutaneously on fixed days (e.g., Monday and Thursday). LL-37 is taken every other day, ideally in the morning. Both peptides are well-tolerated with minimal reported side effects, making this an excellent entry point for those new to peptide protocols. This stack is ideal for individuals with frequent infections, seasonal immune challenges, those recovering from illness, or anyone seeking proactive immune system maintenance. Research supports Thymosin Alpha-1 as a potent immunomodulator in clinical settings, while LL-37 studies demonstrate its role in wound healing, biofilm disruption, and mucosal immunity. A standard protocol runs 4-8 weeks with reassessment.

Dosing Protocol

Thymosin Alpha-1

Twice per week

Read more about Thymosin Alpha-1 →

1,500 mcg

per dose

LL-37

Every other day

Read more about LL-37 →

100 mcg

per dose

Goals & Evidence

Evidence tier:community

Comments

Sign in to join the discussion

Disclaimer: This stack is community-submitted and for research purposes only. Peptide Contacts does not verify the safety or efficacy of submitted stacks. Always consult a qualified healthcare professional before using any peptide protocol.